Does DARATUMUMAB Cause Mobility decreased? 15 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 15 reports of Mobility decreased have been filed in association with DARATUMUMAB (DARZALEX). This represents 0.1% of all adverse event reports for DARATUMUMAB.
15
Reports of Mobility decreased with DARATUMUMAB
0.1%
of all DARATUMUMAB reports
0
Deaths
9
Hospitalizations
How Dangerous Is Mobility decreased From DARATUMUMAB?
Of the 15 reports, 9 (60.0%) required hospitalization.
Is Mobility decreased Listed in the Official Label?
Yes, Mobility decreased is listed as a known adverse reaction in the official FDA drug label for DARATUMUMAB.
What Other Side Effects Does DARATUMUMAB Cause?
Plasma cell myeloma (2,980)
Infusion related reaction (2,557)
Off label use (2,494)
Pneumonia (1,450)
Neutropenia (1,351)
Drug ineffective (1,110)
Thrombocytopenia (1,089)
Death (1,088)
Pyrexia (1,032)
Dyspnoea (996)
What Other Drugs Cause Mobility decreased?
ADALIMUMAB (8,829)
ETANERCEPT (8,321)
METHOTREXATE (5,936)
ABATACEPT (4,519)
TOCILIZUMAB (4,403)
LEFLUNOMIDE (4,354)
HYDROXYCHLOROQUINE (4,105)
RITUXIMAB (4,067)
INFLIXIMAB (3,784)
TOFACITINIB (3,734)
Which DARATUMUMAB Alternatives Have Lower Mobility decreased Risk?
DARATUMUMAB vs DARATUMUMAB\HYALURONIDASE-FIHJ
DARATUMUMAB vs DARBEPOETIN ALFA
DARATUMUMAB vs DARIDOREXANT
DARATUMUMAB vs DARIFENACIN HYDROBROMIDE
DARATUMUMAB vs DAROLUTAMIDE